Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding

Summary Astellas has declined to exercise its option on AviadoBio’s AAV-based gene therapy program targeting frontotemporal dementia (FTD), but the program will continue through nonprofit funding support. The development highlights an alternative pathway for sustaining high-risk, rare-disease programs despite pharmaceutical partner exit. What Happened Astellas,…